Handel Citius Pharmaceuticals, Inc. - CTXR CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.0382 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.025457% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.003235% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Citius Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Nøglestatistikker
| Tidligere luk* | 1.2361 |
| Åben* | 1.2461 |
| 1-Års Ændring* | 41.6% |
| Dagens Spænd* | 1.2261 - 1.286 |
| 52-Ugers Spænd | 0.77-1.71 |
| Gennemsnitlig Volumen (10 dage) | 1.19M |
| Gennemsnitlig Volumen (3 måneder) | 30.29M |
| Market Cap | 196.98M |
| P/E-forhold | -100.00K |
| Udestående aktier | 158.86M |
| Omsætning | N/A |
| EPS | -0.21 |
| Dividend (Udbytte %) | N/A |
| Beta | 1.39 |
| Næste indtjeningsopgørelse | Aug 9, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 1.2859 | 0.0398 | 3.19% | 1.2461 | 1.3059 | 1.2162 |
| Jun 1, 2023 | 1.2361 | 0.0897 | 7.82% | 1.1464 | 1.2959 | 1.1364 |
| May 31, 2023 | 1.1364 | 0.0399 | 3.64% | 1.0965 | 1.1464 | 1.0965 |
| May 30, 2023 | 1.0965 | -0.0100 | -0.90% | 1.1065 | 1.1364 | 1.0965 |
| May 26, 2023 | 1.1065 | 0.0299 | 2.78% | 1.0766 | 1.1165 | 1.0766 |
| May 25, 2023 | 1.0766 | -0.0498 | -4.42% | 1.1264 | 1.1264 | 1.0666 |
| May 24, 2023 | 1.1065 | 0.0200 | 1.84% | 1.0865 | 1.1364 | 1.0666 |
| May 23, 2023 | 1.0965 | -0.0299 | -2.65% | 1.1264 | 1.1464 | 1.0666 |
| May 22, 2023 | 1.1264 | -0.0399 | -3.42% | 1.1663 | 1.1763 | 1.1264 |
| May 19, 2023 | 1.1663 | 0.0199 | 1.74% | 1.1464 | 1.1763 | 1.1264 |
| May 18, 2023 | 1.1165 | 0.0100 | 0.90% | 1.1065 | 1.1564 | 1.0866 |
| May 17, 2023 | 1.0866 | -0.1694 | -13.49% | 1.2560 | 1.2561 | 1.0467 |
| May 16, 2023 | 1.2461 | 0.0000 | 0.00% | 1.2461 | 1.2660 | 1.2261 |
| May 15, 2023 | 1.2660 | -0.1296 | -9.29% | 1.3956 | 1.4056 | 1.2261 |
| May 12, 2023 | 1.3956 | 0.0498 | 3.70% | 1.3458 | 1.4355 | 1.2860 |
| May 11, 2023 | 1.2959 | 0.0199 | 1.56% | 1.2760 | 1.4355 | 1.2760 |
| May 10, 2023 | 1.2461 | 0.0100 | 0.81% | 1.2361 | 1.2860 | 1.1962 |
| May 9, 2023 | 1.2261 | -0.0399 | -3.15% | 1.2660 | 1.2760 | 1.2261 |
| May 8, 2023 | 1.2660 | -0.0100 | -0.78% | 1.2760 | 1.2959 | 1.2461 |
| May 5, 2023 | 1.2660 | 0.0000 | 0.00% | 1.2660 | 1.2959 | 1.2361 |
Citius Pharmaceuticals, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| Wednesday, August 9, 2023 | ||
| Tid (UTC) (UTC) 10:59 | Land US
| Begivenhed Q3 2023 Citius Pharmaceuticals Inc Earnings Release Q3 2023 Citius Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 33.3161 | 23.3653 | 17.7107 | 15.5984 | 13.3391 |
| Salgs/Generelle/Admin. Udgifter, Total | 15.6606 | 11.2914 | 8.89788 | 7.00146 | 7.22622 |
| Forskning & Udvikling | 17.6555 | 12.2405 | 8.81281 | 8.5969 | 6.56293 |
| Driftsindtægter | -33.3161 | -23.3653 | -17.7107 | -15.5984 | -13.3391 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.2514 | 0.25099 | 0.0524 | 0.03622 | -0.01584 |
| Netto Indkomst Før Skat | -33.0647 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Netto Indkomst Efter Skat | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Netto Indkomst Før Ekstra Ting | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Netto Indkomst | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Fortyndet Netto Indkomst | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Fortyndet Vægtet Gennemsnit Aktier | 146.082 | 108.599 | 39.1652 | 20.1618 | 10.7319 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.23029 | -0.22565 | -0.44805 | -0.77186 | -1.16817 |
| Fortyndet Normaliseret EPS | -0.23029 | -0.22718 | -0.44805 | -0.77186 | -1.2101 |
| Usædvanlig Udgift (Indkomst) | 0 | -0.16656 | 0 | -0.45 | |
| Andre, Netto | 0 | 0.05992 | 0.11021 | 0 | 0.81834 |
| Total Adjustments to Net Income | 0 | -1.45088 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 10.6853 | 3.66419 | 7.54957 | 8.91665 | 7.59063 |
| Salgs/Generelle/Admin. Udgifter, Total | 5.95845 | 3.80437 | 3.69234 | 4.02846 | 4.13842 |
| Forskning & Udvikling | 4.72686 | 3.44552 | 3.85723 | 4.88819 | 3.45221 |
| Driftsindtægter | -10.6853 | -3.66419 | -7.54957 | -8.91665 | -7.59063 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.30328 | 0.21455 | 0.13483 | 0.05302 | 0.02957 |
| Andre, Netto | 0 | 0 | |||
| Netto Indkomst Før Skat | -10.382 | -3.44965 | -7.41474 | -8.86363 | -7.56105 |
| Netto Indkomst Efter Skat | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Netto Indkomst Før Ekstra Ting | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Netto Indkomst | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Fortyndet Netto Indkomst | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Fortyndet Vægtet Gennemsnit Aktier | 146.252 | 146.211 | 146.146 | 146.13 | 146.042 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.07197 | -0.02458 | -0.05468 | -0.06066 | -0.05177 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.07197 | -0.04052 | -0.05468 | -0.06066 | -0.05177 |
| Total Adjustments to Net Income | 0 | 0 | |||
| Usædvanlig Udgift (Indkomst) | 0 | -3.58569 | 0 |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 44.5643 | 72.8143 | 13.982 | 7.94192 | 10.0601 |
| Likvider og Kortsigtede Investeringer | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Likvider & Lignende | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Prepaid Expenses | 2.85258 | 2.7414 | 0.12224 | 0.04811 | 0.05773 |
| Total Assets | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Property/Plant/Equipment, Total - Net | 0.65017 | 0.82985 | 0.98778 | 0.00059 | 0.00148 |
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 1.5868 |
| Intangibles, Net | 59.4 | 59.4 | 19.4 | 19.4 | 19.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.05709 | 0.05709 | 0.00217 |
| Total Current Liabilities | 4.53001 | 3.98229 | 4.09713 | 4.60772 | 3.18484 |
| Accounts Payable | 1.16538 | 1.2771 | 1.85624 | 2.71354 | 1.57344 |
| Accrued Expenses | 3.36463 | 2.7052 | 2.06793 | 1.72121 | 1.43843 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.17297 | 0.17297 | 0.17297 |
| Other Current Liabilities, Total | 0 | ||||
| Total Liabilities | 11.1734 | 10.2467 | 10.103 | 9.59352 | 3.18484 |
| Total Long Term Debt | 0 | 0 | 0.16458 | 0 | 0 |
| Total Equity | 102.826 | 132.182 | 33.6707 | 27.1529 | 27.8657 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.14621 | 0.14598 | 0.05558 | 0.02893 | 0.0162 |
| Additional Paid-In Capital | 232.368 | 228.084 | 104.209 | 80.1697 | 68.1073 |
| Retained Earnings (Accumulated Deficit) | -129.688 | -96.0478 | -70.5939 | -53.0458 | -40.2578 |
| Total Liabilities & Shareholders’ Equity | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Total Common Shares Outstanding | 146.211 | 145.979 | 55.577 | 28.9305 | 16.1988 |
| Totale Tilgodehavender, Netto | 0.81834 | ||||
| Long Term Debt | 0 | 0.16458 | 0 | ||
| Deferred Income Tax | 5.5618 | 4.9858 | 4.9858 | 4.9858 | |
| Other Liabilities, Total | 0.48125 | 0.67823 | 0.85547 | ||
| Minority Interest | 0.60038 | 0.60038 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 34.9011 | 42.3174 | 44.5643 | 50.8345 | 58.2593 |
| Likvider og Kortsigtede Investeringer | 29.0655 | 36.8872 | 41.7117 | 48.0442 | 55.7562 |
| Likvider & Lignende | 29.0655 | 36.8872 | 41.7117 | 48.0442 | 55.7562 |
| Prepaid Expenses | 5.8356 | 5.43013 | 2.85258 | 2.79032 | 2.50311 |
| Total Assets | 104.241 | 111.705 | 113.999 | 120.316 | 127.786 |
| Property/Plant/Equipment, Total - Net | 0.55484 | 0.60299 | 0.65017 | 0.69642 | 0.74177 |
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 9.3468 |
| Intangibles, Net | 59.4 | 59.4 | 59.4 | 59.4 | 59.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.03806 | 0.03806 | 0.03806 |
| Total Current Liabilities | 6.20968 | 4.53717 | 4.53001 | 4.46112 | 4.02192 |
| Accounts Payable | 2.72559 | 1.53758 | 1.16538 | 1.69052 | 1.70513 |
| Accrued Expenses | 3.48408 | 2.99959 | 3.36463 | 2.7706 | 2.3168 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 13.0347 | 11.2719 | 11.1734 | 10.5802 | 10.1904 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Deferred Income Tax | 5.8498 | 5.7058 | 5.5618 | 4.9858 | 4.9858 |
| Minority Interest | 0.60038 | 0.60038 | 0.60038 | 0.60038 | 0.60038 |
| Other Liabilities, Total | 0.37483 | 0.42857 | 0.48125 | 0.53288 | 0.5823 |
| Total Equity | 91.2061 | 100.433 | 102.826 | 109.736 | 117.596 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.14636 | 0.14621 | 0.14621 | 0.14613 | 0.14613 |
| Additional Paid-In Capital | 234.868 | 233.569 | 232.368 | 231.287 | 230.284 |
| Retained Earnings (Accumulated Deficit) | -143.808 | -133.282 | -129.688 | -121.698 | -112.834 |
| Total Liabilities & Shareholders’ Equity | 104.241 | 111.705 | 113.999 | 120.316 | 127.786 |
| Total Common Shares Outstanding | 146.358 | 146.211 | 146.211 | 146.13 | 146.13 |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Likvider Fra Driftsaktiviteter | -28.3613 | -24.2504 | -16.9307 | -12.4377 | -11.3181 |
| Likvider Fra Driftsaktiviteter | 0.00292 | 0.00149 | 0.00084 | 0.00089 | 0.00175 |
| Ikke-Likvide Ting | 4.46091 | 1.5198 | 1.48355 | 0.92758 | 0.7069 |
| Cash Taxes Paid | |||||
| Likvid Rente Betalt | 0 | 0.00019 | |||
| Ændringer i Driftskapital | 0.23956 | -2.71727 | -0.86697 | 2.19592 | 0.50985 |
| Likvider fra Investeringsaktiviteter | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Andre Investerings-Cash-Flow-Ting, Total | 0 | ||||
| Likvider fra Financieringsaktiviteter | 0 | 120.471 | 22.8984 | 11.1475 | 17.298 |
| Financiering af Cash-Flow-Ting | 0 | 18.4504 | 0 | 0 | |
| Udstedelse (Pensionering) af Gæld, Netto | 0 | -0.17297 | 0.16458 | 0 | 0 |
| Netto Ændring i Likviditet | -28.3613 | 56.2132 | 5.96594 | -1.2902 | 5.9799 |
| Kapitaludgifter | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Udstedelse (Pensionering) af Aktier, Netto | 0 | 102.193 | 22.7339 | 11.1475 | 17.298 |
| Deferred Taxes | 0.576 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.1197 | -3.59365 | -33.6407 | -25.6499 | -16.7863 |
| Cash From Operating Activities | -12.6774 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Operating Activities | 0.00146 | 0.00073 | 0.00292 | 0.00219 | 0.00146 |
| Non-Cash Items | 2.56255 | 1.24754 | 4.46091 | 3.3344 | 2.28611 |
| Changes in Working Capital | -1.40977 | -2.62306 | 0.23956 | 0.28456 | 0.18199 |
| Cash From Financing Activities | 0.03127 | 0 | 0 | 0 | 0 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.03127 | 0 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
| Net Change in Cash | -12.6462 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Investing Activities | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | |||
| Deferred Taxes | 0.288 | 0.144 | 0.576 | ||
| Other Investing Cash Flow Items, Total | 0 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Mazur (Leonard L) | Individual Investor | 6.4557 | 10255342 | -1 | 2022-11-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8112 | 6054328 | 40301 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 1.5265 | 2425000 | -3743361 | 2021-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4586 | 2317168 | 4868 | 2023-03-31 | LOW |
| Holubiak (Myron Z) | Individual Investor | 1.2541 | 1992243 | 0 | 2022-11-30 | |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8428 | 1338777 | 6154 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3 | 476597 | 34000 | 2023-03-31 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.2893 | 459511 | 130223 | 2023-03-31 | MED |
| GSA Capital Partners LLP | Hedge Fund | 0.2849 | 452561 | -46222 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.2513 | 399270 | -9900 | 2023-03-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.1917 | 304482 | -246644 | 2023-03-31 | HIGH |
| Jane Street Capital, L.L.C. | Research Firm | 0.1549 | 246023 | 224990 | 2023-03-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1541 | 244755 | 7008 | 2023-03-31 | LOW |
| Hightower Advisors, LLC | Investment Advisor | 0.1317 | 209198 | 14713 | 2023-03-31 | LOW |
| Inspire Advisors, LLC | Investment Advisor | 0.125 | 198632 | 2686 | 2023-03-31 | LOW |
| Wealth Advisory Solutions, L.L.C. | Investment Advisor | 0.0981 | 155850 | 0 | 2023-03-31 | MED |
| AHL Partners LLP | Investment Advisor | 0.0836 | 132826 | 86615 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0759 | 120521 | 31943 | 2023-03-31 | MED |
| Qube Research & Technologies Ltd | Hedge Fund | 0.063 | 100106 | -20474 | 2023-03-31 | HIGH |
| Kestra Advisory Services, LLC | Investment Advisor | 0.0579 | 91917 | -1800 | 2023-03-31 | MED |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group535K+
Handlende
87K+
Månedlkige, aktive klienter
$113M+
Månedlig investeringsvolumen
$64M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Citius Pharmaceuticals, Inc. Company profile
Om Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc. er en specialiseret lægemiddelvirksomhed. Virksomheden udvikler og markedsfører produkter til kritisk pleje med fokus på anti-infektive produkter som supplement til kræftbehandling, receptpligtige produkter og mesenchymal stamcelleterapi. Virksomheden har fem produkter: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite og I/ONTAK. Mino-Lok er en antibiotikalås, der anvendes til behandling af patienter med kateterrelaterede blodstrømsinfektioner ved at redde det inficerede kateter. Mino-Wrap er en flydende gelbaseret indpakning til reduktion af vævsekspanderinfektioner efter rekonstruktive brystoperationer. Halo-Lido er en kortikosteroid-lidocain-formulering til lokal anvendelse, som er beregnet til at give antiinflammatorisk og bedøvende lindring til personer, der lider af hæmorider. NoveCite er en behandling med mesenkymale stamceller til behandling af ARDS. I/ONTAK er et manipuleret IL-2 difteritoksin-fusionsprotein til behandling af patienter med persisterende eller tilbagevendende kutant T-celle lymfom.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Commerce Dr Fl 1
CRANFORD
NEW JERSEY 07016-3501
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com